Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells

Severe eosinophilic asthma (SEA) is a therapy-resistant respiratory condition with poor clinical control. Treatment efficacy and patient compliance of current therapies remain unsatisfactory. Here, inspired by the remarkable success of chimeric antigen receptor-based cellular adoptive immunotherapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sisi, Chen, Gaoying, Xu, Fang, Sun, Beibei, Chen, Xinyi, Hu, Wei, Li, Fei, Syeda, Madiha Zahra, Chen, Haixia, Wu, Youqian, Wu, Peng, Jing, Ruirui, Geng, Xinwei, Zhang, Lingling, Tang, Longguang, Li, Wen, Chen, Zhihua, Zhang, Chao, Sun, Jie, Chen, Wei, Shen, Huahao, Ying, Songmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381771/
https://www.ncbi.nlm.nih.gov/pubmed/35973984
http://dx.doi.org/10.1038/s41421-022-00433-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381771/
https://www.ncbi.nlm.nih.gov/pubmed/35973984
http://dx.doi.org/10.1038/s41421-022-00433-y

Ejemplares similares